Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a report released on Tuesday morning.

Other analysts have also recently issued reports about the stock. Canaccord Genuity Group lowered their price objective on shares of Seres Therapeutics from $15.00 to $10.00 and set a buy rating for the company in a research note on Friday, June 7th. Chardan Capital dropped their price target on Seres Therapeutics from $8.00 to $6.00 and set a buy rating for the company in a research note on Wednesday, May 8th. Finally, Oppenheimer reaffirmed a market perform rating on shares of Seres Therapeutics in a research note on Friday, June 7th.

Seres Therapeutics Trading Down 0.9 %

Shares of NASDAQ:MCRB opened at $0.98 on Tuesday. The firm has a market cap of $148.12 million, a price-to-earnings ratio of -1.63 and a beta of 1.98. The stock’s 50-day moving average price is $0.87 and its two-hundred day moving average price is $0.96. Seres Therapeutics has a 12-month low of $0.54 and a 12-month high of $5.29.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.09. As a group, research analysts forecast that Seres Therapeutics will post -1.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Hudson Bay Capital Management LP raised its holdings in shares of Seres Therapeutics by 127.3% during the 3rd quarter. Hudson Bay Capital Management LP now owns 1,999,800 shares of the biotechnology company’s stock valued at $4,760,000 after buying an additional 1,119,800 shares during the period. Vanguard Group Inc. grew its position in Seres Therapeutics by 12.1% in the first quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock valued at $5,213,000 after acquiring an additional 729,514 shares in the last quarter. Pennant Investors LP purchased a new stake in shares of Seres Therapeutics during the fourth quarter valued at approximately $409,000. Graham Capital Management L.P. lifted its position in shares of Seres Therapeutics by 731.3% during the third quarter. Graham Capital Management L.P. now owns 206,838 shares of the biotechnology company’s stock worth $492,000 after purchasing an additional 181,957 shares in the last quarter. Finally, Handelsbanken Fonder AB boosted its stake in shares of Seres Therapeutics by 10.0% in the fourth quarter. Handelsbanken Fonder AB now owns 1,100,000 shares of the biotechnology company’s stock valued at $1,540,000 after purchasing an additional 100,000 shares during the period. 59.34% of the stock is owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.